|[September 28, 2013]
Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of BioScrip, Inc.
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of shareholders of BioScrip,
Inc. ("BioScrip" or the "Company") (NASDAQ:BIOS) concerning possible
breaches of fiduciary duties by the Company or its fiduciaries. The
investigation is focused on certain statements issued by the Company
concerning BioScrip's business and operations.
Please contact us at 212-682-5340, Toll-Free at 888-773-9224, or at firstname.lastname@example.org
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
BioScrip provides home infusion, other home care services, and pharmacy
benefit management services in the United States. On September 23, 2013,
the Company disclosedthat the United States Attorney's Office for the
Southern District of New York and the New York State Attorney General's
Medicaid Fraud Control Unit have undertaken an investigation regarding
the distribution of the Novartis Pharmaceuticals Corporation product
Exjade(R) by the Company's legacy specialty pharmacy
division. The Company further disclosed that it has provided documents
and information to the government regarding the distribution of Exjade,
pursuant to a civil investigative demand and a subpoena. Following this
news, the price of BioScrip shares declined more than 18%, to a closing
price of $8.47 per share on September 24, 2013.
If you purchased BioScrip shares and still hold those shares, if you
have information or would like to learn
more about these claims, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at
888-773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at 212-682-5340, by e-mail
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To Technology News's Homepage ]